Historically, the process of documenting clinical data for trials has been fraught with redundancies and inefficiencies. Clinical research teams have long grappled with the tedious task of manually re-entering patient information into multiple disparate systems. This manual transcription, often duplicated across electronic data capture (EDC) systems and specialized trial databases, not only hampers workflow efficiency but also introduces risks of transcription errors, delays, and increased administrative overhead. The new integration at Mount Sinai eradicates these pain points by enabling automatic, real-time data synchronization between Epic and clinical trial databases.

The critical technological backbone facilitating this leap in research data management is the adoption of HL7® FHIR® standards. These healthcare-specific interoperability standards provide a universal language and framework, ensuring that the transfer of structured clinical data occurs securely, consistently, and with impeccable fidelity. By harnessing these protocols, Archer automates data flow into sponsor EDC systems, eliminating manual entry and thereby preserving data integrity from the point of capture during patient visits.

Early pilot studies underscore the profound impact of this integration, showing a staggering reduction of up to 70 percent in manual transcription time. The resultant gains extend beyond simple time savings; accuracy in data recording is significantly enhanced, mitigating risks of human error that can compromise trial validity. Furthermore, these efficiencies free clinical research staff to dedicate more energy toward patient interaction and study oversight rather than administrative tasks, a vital step in combating professional burnout and optimizing resource allocation.

Beyond operational efficiencies, the automated data transfer framework accelerates regulatory review and safety monitoring. As aggregated safety and trial data becomes available sooner, oversight bodies can more promptly identify emerging trends or safety concerns. This real-time vigilance not only ensures patient safety but also expedites regulatory decision-making, thereby shortening the timeline for bringing promising new therapies from concept to clinic.

Dr. Karyn Goodman, a leading figure in the Department of Radiation Oncology and Vice Chair of Clinical Research at Mount Sinai, heralds this integration as a pivotal moment in the conduct of clinical trials. She emphasizes that the automation and enhanced data accuracy directly translate into the ability to conduct more studies, engage a broader patient cohort, and deliver innovative treatments with greater speed and reliability.

The adoption of this cutting-edge data infrastructure aligns seamlessly with Mount Sinai Tisch Cancer Center’s recent designation as a National Cancer Institute Comprehensive Cancer Center. Such designations evaluate institutions not only on scientific innovation but also on operational excellence—particularly their ability to conduct complex, multicenter trials with high fidelity to data integrity and regulatory compliance. By showcasing advanced electronic systems capable of real-time, accurate, and secure data submission, Mount Sinai sets a new standard for research infrastructure maturity.

Therica Miller, Executive Director of Enterprise Cancer Clinical Research at Mount Sinai Tisch Cancer Institute, notes that this technological evolution profoundly benefits the specialized research workforce. Their expertise is now better utilized in patient-facing roles rather than redundant clerical work, reducing burnout while significantly expanding the center’s capacity to initiate and manage more clinical trials across diverse populations.

Currently, this innovative system is fully operational within Mount Sinai’s oncology services, representing a significant milestone in clinical trial data management. Plans are underway to extend this integration across other specialty areas, heralding an era where automated, real-time clinical data exchange becomes the norm in medical research.

Underlying this technological breakthrough is the Icahn School of Medicine at Mount Sinai’s commitment to pioneering research and delivering exceptional clinical care. With deep ties to seven member hospitals in the Mount Sinai Health System and an extensive network of scientists, clinicians, and educators, the institution continues to push the envelope in translational research and therapeutic development.

Ranking 11th nationally in National Institutes of Health funding, the Icahn School of Medicine at Mount Sinai exemplifies research excellence and innovation. By leveraging platforms like IgniteData’s Archer in conjunction with Epic, this institution not only innovates at the molecular and treatment levels but also innovates how clinical data flows, fundamentally altering the landscape of clinical research.

This fusion of sophisticated data interoperability standards and advanced health informatics tools illuminates a future where clinical trials are not only more efficient and accurate but also more inclusive and responsive. As data moves fluidly, securely, and instantly from point of care to trial databases, the potential to accelerate the development of transformative oncology treatments is vastly increased, impacting patient outcomes worldwide.

The Mount Sinai Tisch Cancer Center’s pioneering automation is a shining example of how integrating technology with clinical expertise can overcome longstanding barriers in medical research. By streamlining data processes, enhancing safety oversight, and reducing administrative fatigue, this initiative propels both the science and humanity of cancer research into a new era of possibility.

Subject of Research:
Clinical data automation and integration for cancer clinical trials using HL7® FHIR® standards within electronic health records

Article Title:
Mount Sinai Advances Cancer Clinical Trials with Automated Integration of Electronic Health Records and Trial Platforms

News Publication Date:
Information not provided

Web References:
Information not provided

References:
Information not provided

Image Credits:
Information not provided

Keywords:
Cancer research, Clinical trials, Electronic health records, Data automation, HL7 FHIR standards, Clinical data integration, Oncology research, Clinical trial efficiency, Patient data security, Translational medicine, Healthcare interoperability

Flatiron Clinical Pipe™ is set to play a pivotal role in transforming how clinical data is collected and managed within multicenter trials, particularly those sponsored by the National Clinical Trials Network (NCTN). This collaboration marks a significant step toward optimizing data management workflows, as it provides a direct connection between the electronic health records used in clinical settings and the systems utilized for data entry during trials. By effectively bridging this gap, the partnership is poised to accelerate study timelines, facilitating faster and more reliable results.

The partnership between Flatiron and NRG Oncology exemplifies a forward-thinking approach to clinical trials, wherein the focus is placed on reducing the manual labor associated with data entry. By employing Flatiron Clinical Pipe™, research teams can expect to see a significant decrease in the time and effort currently required for data management, which will ultimately lead to improved efficiencies in conducting trials. As the two organizations work together, they will also conduct a correlative study to systematically analyze the efficiency gains achieved through this technological integration, comparing it against traditional data entry methodologies.

Alex Deyle, the General Manager of Clinical Research at Flatiron Health, highlighted the importance of this collaboration, stating that it presents a remarkable opportunity to redefine the clinical trial experience. The integration of Flatiron Clinical Pipe™ is expected to yield higher quality data and a more efficient process for data acquisition, which is essential for generating valuable evidence in cancer research. Deyle emphasized that placing cutting-edge technology in the hands of research teams not only enhances efficiency but also allows for a more focused approach to patient care, a critical factor in oncology research.

Moreover, a recent study published in the journal ESMO Real World Data and Digital Oncology illustrated the effectiveness of Flatiron Clinical Pipe™. The research demonstrated that teams using this technology were able to accurately transfer thousands of data points in a remarkably short time frame—approximately 37 seconds to complete and submit a case report form (CRF). This represents a substantial time-saving advantage, thereby allowing clinical trial providers to dedicate more meaningful interactions to patient care, elevating the overall experience for both patients and researchers involved.

The implications of this collaboration extend beyond simply improving operational efficiencies. Alexandra Thomas, MD, FACP, Vice Chair of NRG Protocol Operation Management, expressed her excitement about the potential of this partnership. She noted that harnessing the strengths of Flatiron’s healthcare systems technology, particularly through Clinical Pipe, promises to enhance the accuracy and speed of clinical trial results delivery. Such operational advancements align with NRG Oncology’s mission to reduce cancer-related suffering and provide more effective interventions for patients battling the disease.

In addition to facilitating workflow enhancements and data accuracy, the collaboration between Flatiron and NRG Oncology represents broader implications for the future of oncology clinical trials. By leveraging machine learning, artificial intelligence, and real-world evidence, both organizations are committed to transforming patient experiences and creating a more interconnected oncology ecosystem. This endeavor asserts a paradigm shift in how clinical data is utilized, ultimately shaping research methodologies and improving therapeutic strategies within oncology.

As the healthcare landscape continues to evolve toward utilizing data for improved patient outcomes, collaborations like the one between Flatiron Health and NRG Oncology exemplify the power of technology inclinical research. The integration of such technological innovations has the potential to foster an era of more efficient, patient-centered care pathways, addressing unmet needs within the oncology field and enhancing clinical trial accessibility for a wider patient population.

Furthermore, the deployment of Flatiron Clinical Pipe™ within NCTN studies underscores the importance of collaborative efforts in clinical research. By combining the expertise of Flatiron, a leader in health technology, with the extensive research capabilities of NRG Oncology, this partnership is set to redefine the expectations surrounding clinical trial experiences. Additionally, it paints a promising picture of how strategic collaborations can lead to groundbreaking advancements that benefit not only the research community but patients who stand to gain from improved care models and treatment protocols.

In conclusion, the collaboration between Flatiron Health and NRG Oncology marks a significant milestone in the quest to revolutionize clinical trials through technology. By implementing Flatiron Clinical Pipe™, the collaboration is expected to yield a plethora of benefits that include enhanced data quality, reduced administrative burdens, and improved patient care experiences. This initiative highlights the ongoing commitment of both organizations to leverage innovative solutions to drive efficiencies in clinical research and ultimately improve the lives of those affected by cancer.

Subject of Research: Integration of electronic health records in clinical trials
Article Title: Flatiron Health and NRG Oncology Collaborate to Enhance Clinical Trial Efficiency
News Publication Date: October 23, 2023
Web References: Flatiron Health, NRG Oncology
References: Pfeffer, M. et al. ESMO Real World Data and Digital Oncology, Volume 7, 100112. DOI: 10.1016/j.esmorw.2025.100112
Image Credits: N/A
Keywords: Clinical trials, electronic health records, data management, oncology research, technology integration.